ARIPIPRAZOLE IN TOURETTE'S DISORDER AND EXPLOSIVE OUTBURSTS

阿立哌唑治疗抽动秽语症和爆发性发作

• 批准号: 7605767
• 负责人: BARBARA Jane COFFEY
• 金额: $ 0.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605767
• 关键词: Adolescent; Adult; Anger; Bipolar Disorder; Child; Computer Retrieval of Information on Scientific Projects Database; Dose; End Point; Frequencies; Funding; Gilles de la Tourette syndrome; Grant; Individual; Institution; Measures; Numbers; Persons; Pharmaceutical Preparations; Placebo Control; Placebos; Rage; Range; Research; Research Personnel; Resources; Safety; Severities; Source; Testing; United States National Institutes of Health; aripiprazole; neuropsychiatry; treatment effect; week trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that aripiprazole, which has been shown to be effective in the treatment of psychotic and manic-depressive disorders, will be more effective than placebo in reducing the severity of explosive outbursts in children and adolescents with Tourette's Disorder (TD), as assessed by measuring the frequency, intensity, and duration of explosive outbursts. The study will test the efficacy and safety of a relatively safe drug when used in adults as a treatment of TD in children and adolescents. The endpoints are a variety of different neuropsychiatric tests, administered by the staff, that will measure tic, frequency, anger, range, and outbursts. A newly devised test, the Rage Severity Scale, will be administered, and the effects of treatment measured on this scale will be compared to more traditional assessments. The study is a placebo-controlled, 6-week trial with increasing doses of aripiprazole versus placebo. Treatment and placebo groups of 15 are planned, as early information suggests a very significant impact of this drug in TD (p<10-12) using a small number of treated individuals. Within-person changes will be assessed longitudinally.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究假设，阿立哌唑已被证明可有效治疗精神病和躁狂抑郁症，通过测量爆发性爆发的频率、强度和持续时间进行评估，阿立哌唑在降低抽动秽语症 (TD) 儿童和青少年爆发性爆发的严重程度方面将比安慰剂更有效。 该研究将测试一种相对安全的药物用于成人治疗儿童和青少年 TD 的有效性和安全性。 终点是由工作人员进行的各种不同的神经精神测试，这些测试将测量抽动、频率、愤怒、范围和爆发。 将进行一项新设计的测试，即愤怒严重程度量表，并将根据该量表测量的治疗效果与更传统的评估进行比较。 该研究是一项为期 6 周的安慰剂对照试验，与安慰剂相比，阿立哌唑的剂量逐渐增加。 治疗组和安慰剂组均计划 15 人，因为早期信息表明该药物对少数接受治疗的个体对 TD 产生非常显着的影响 (p<10-12)。 将纵向评估人员内部的变化。